EMERPHED Drug Patent Profile
✉ Email this page to a colleague
When do Emerphed patents expire, and when can generic versions of Emerphed launch?
Emerphed is a drug marketed by Nexus and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has ten patent family members in nine countries.
The generic ingredient in EMERPHED is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emerphed
A generic version of EMERPHED was approved as ephedrine sulfate by SANDOZ on August 23rd, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMERPHED?
- What are the global sales for EMERPHED?
- What is Average Wholesale Price for EMERPHED?
Summary for EMERPHED
International Patents: | 10 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Patent Applications: | 551 |
Drug Prices: | Drug price information for EMERPHED |
What excipients (inactive ingredients) are in EMERPHED? | EMERPHED excipients list |
DailyMed Link: | EMERPHED at DailyMed |
Pharmacology for EMERPHED
Drug Class | Norepinephrine Releasing Agent alpha-Adrenergic Agonist beta-Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
Physiological Effect | Increased Norepinephrine Activity |
Paragraph IV (Patent) Challenges for EMERPHED
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
EMERPHED | Injection | ephedrine sulfate | 50 mg/10 mL | 213407 | 1 | 2021-10-14 |
US Patents and Regulatory Information for EMERPHED
EMERPHED is protected by five US patents.
Patents protecting EMERPHED
Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION
Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-002 | Feb 28, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-001 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-001 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-002 | Feb 28, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-001 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-001 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-001 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EMERPHED
See the table below for patents covering EMERPHED around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2020276619 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | ⤷ Sign Up |
Japan | 2023091072 | エフェドリンまたはエフェドリン塩を含む組成物ならびにその組成物を作製する方法および使用する方法 (COMPOSITIONS COMPRISING EPHEDRINE OR EPHEDRINE SALT AND METHODS OF MAKING AND USING THOSE COMPOSITIONS) | ⤷ Sign Up |
South Korea | 20220009985 | 에페드린 또는 에페드린 염을 포함하는 조성물 및 그의 제조 및 사용 방법 | ⤷ Sign Up |
Japan | 2022532657 | エフェドリンまたはエフェドリン塩を含む組成物ならびにその組成物を作製する方法および使用する方法 | ⤷ Sign Up |
European Patent Office | 3968975 | COMPOSITIONS COMPRENANT DE L'ÉPHÉDRINE OU UN SEL D'ÉPHÉDRINE ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION (COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME) | ⤷ Sign Up |
China | 113825500 | 包含麻黄碱或麻黄碱盐的组合物及其制备和使用方法 (COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME) | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2020232424 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EMERPHED
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1110543 | 08C0004 | France | ⤷ Sign Up | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
1110543 | SPC/GB08/005 | United Kingdom | ⤷ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |